Crinetics Pharmaceuticals Gestione
Gestione criteri di controllo 3/4
Crinetics Pharmaceuticals Il CEO è R. Struthers, nominato in Dec2008, e ha un mandato di 15.92 anni. la retribuzione annua totale è $ 5.75M, composta da 10.7% di stipendio e 89.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.1% delle azioni della società, per un valore di $ 57.26M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 3.3 anni e 4.2 anni.
Informazioni chiave
R. Struthers
Amministratore delegato
US$5.7m
Compenso totale
| Percentuale dello stipendio del CEO | 10.7% |
| Mandato del CEO | 15.9yrs |
| Proprietà del CEO | 1.1% |
| Durata media del management | 3.3yrs |
| Durata media del Consiglio di amministrazione | 4.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
We're Hopeful That Crinetics Pharmaceuticals (NASDAQ:CRNX) Will Use Its Cash Wisely
Oct 02
Crinetics Pharmaceuticals: Stop, Look, And Listen Before Buying This High-Priced Clinical Stage Biotech
Aug 12Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation
Jun 01Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data
May 23Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
Feb 29Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Nov 28Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?
Aug 08Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans
Dec 31Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation
Sep 14Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M
Aug 12We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate
Jun 15Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point
Jun 13Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$278m |
| Jun 30 2024 | n/a | n/a | -US$259m |
| Mar 31 2024 | n/a | n/a | -US$235m |
| Dec 31 2023 | US$6m | US$614k | -US$215m |
| Sep 30 2023 | n/a | n/a | -US$199m |
| Jun 30 2023 | n/a | n/a | -US$184m |
| Mar 31 2023 | n/a | n/a | -US$175m |
| Dec 31 2022 | US$6m | US$590k | -US$164m |
| Sep 30 2022 | n/a | n/a | -US$150m |
| Jun 30 2022 | n/a | n/a | -US$136m |
| Mar 31 2022 | n/a | n/a | -US$119m |
| Dec 31 2021 | US$4m | US$567k | -US$108m |
| Sep 30 2021 | n/a | n/a | -US$98m |
| Jun 30 2021 | n/a | n/a | -US$89m |
| Mar 31 2021 | n/a | n/a | -US$79m |
| Dec 31 2020 | US$4m | US$544k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$67m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$59m |
| Dec 31 2019 | US$4m | US$542k | -US$50m |
| Sep 30 2019 | n/a | n/a | -US$44m |
| Jun 30 2019 | n/a | n/a | -US$38m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$3m | US$410k | -US$27m |
| Sep 30 2018 | n/a | n/a | -US$21m |
| Jun 30 2018 | n/a | n/a | -US$16m |
| Mar 31 2018 | n/a | n/a | -US$12m |
| Dec 31 2017 | US$385k | US$350k | -US$9m |
Compensazione vs Mercato: La retribuzione totale di R. ($USD 5.75M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 7.74M ).
Compensazione vs guadagni: La retribuzione di R. è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
R. Struthers (61 yo)
15.9yrs
Mandato
US$5,747,994
Compensazione
Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 15.9yrs | US$5.75m | 1.1% $ 57.3m | |
| Founder & Chief Scientific Officer | 3.1yrs | US$2.50m | 0.021% $ 1.1m | |
| Chief Financial Officer | 6.8yrs | US$2.51m | 0.062% $ 3.2m | |
| Chief Operating Officer | 3.2yrs | US$2.36m | 0.0044% $ 227.2k | |
| Chief Endocrinologist | 6.4yrs | US$2.16m | 0.014% $ 729.9k | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| General Counsel & Corporate Secretary | 3.4yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | 4.5yrs | Nessun dato | Nessun dato | |
| Head of Intellectual Property | no data | Nessun dato | Nessun dato | |
| Chief Business Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Chief Medical & Development Officer | 2.2yrs | US$3.61m | 0.0023% $ 119.6k | |
| Senior Vice President of Medical Affairs | less than a year | Nessun dato | Nessun dato |
3.3yrs
Durata media
59.5yo
Età media
Gestione esperta: Il team dirigenziale di CRNX è considerato esperto (durata media dell'incarico 3.3 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 16yrs | US$5.75m | 1.1% $ 57.3m | |
| Independent Chairman of the Board | 9.1yrs | US$375.31k | 0.11% $ 5.9m | |
| Independent Director | 6.8yrs | US$348.56k | 0.020% $ 1.0m | |
| Independent Director | 4.2yrs | US$339.56k | 0.0065% $ 336.4k | |
| Member of Scientific Advisory Board | no data | Nessun dato | Nessun dato | |
| Independent Director | 2.8yrs | US$338.56k | 0.012% $ 616.6k | |
| Independent Director | 6.8yrs | US$338.56k | 0.0065% $ 336.4k | |
| Independent Director | 5.3yrs | US$342.31k | 0.0065% $ 336.4k | |
| Independent Director | 2.7yrs | US$330.06k | 0.0065% $ 336.4k | |
| Member of Scientific Advisory Board | 2.6yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 2.6yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 2.6yrs | Nessun dato | Nessun dato |
4.2yrs
Durata media
61yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CRNX sono considerati esperti (durata media dell'incarico 4.2 anni).